Health and Healthcare
63 Articles
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical…
Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health…
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…
24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on…
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the…
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and…
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and…
Merrill Lynch singled out a group in the tech sector that the firm believes will outperform going forward -- specifically,…
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's…
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
Trump told Time that he wants to lower drug prices, a move that has hit the drug and biotech segments…
We know that the broad markets work on the basis of greed and fear, but we have to ask ourselves…
Here are four biotech companies that have just either closed fresh financing rounds or issued IPOs that exceeded price expectations.
If the momentum in biotech can continue, then companies with catalysts within the next 12 to 18 months could get…
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Our top personal finance-related articles today. Your wallet will thank you later.